Abbott Looks to Dump 1/3 of its Mylan Stake

Apr 01, 2015


Abbott Laboratories has filed to sell 35 million shares of Mylan stock as the Illinois-based drugmaker took its first step toward unloading its newly-acquired 22% stake in Mylan.

Last July, Abbott sold its drug portfolio in developed overseas markets to Mylan for 105 million shares of Mylan stock, an all-stock deal worth $5.3 billion. The deal allowed Mylan to benefit from a lower tax rate by reorganizing the company in the Netherlands. Under a revised deal, Abbott received a stake of about 22% in the new Mylan.

According to John Divine of InvestorPlace, Abbott "never planned on being a long-term shareholder in Mylan stock anyways; it said as much from the get-go. Abbott stated that it wanted to take the proceeds from the Mylan deal and reallocate them to higher-return projects, which is what the company will now be able to do after selling 32% of its stake."

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments